Dynamic diagnosis of familial prion diseases supports the β2-α2 loop as a universal interference target

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Meli, Massimiliano ^a   Gasset, Maria ^b   Colombo, Giorgio ^a  

^a CNR   (Italy)

^b INSTITUTO DE QUÍMICA FÍSICA ROCASOLANO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMINO ACID; ARGININE; ASPARAGINE; ASPARTIC ACID; GLUTAMIC ACID; GLUTAMINE; HISTIDINE; ISOLEUCINE; LYSINE; PHENYLALANINE; PRION PROTEIN; SERINE; THREONINE; VALINE; METHIONINE; SOLVENT;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING SITE; CONTROLLED STUDY; FAMILIAL DISEASE; HUMAN; MOLECULAR DYNAMICS; MOLECULAR RECOGNITION; MUTATIONAL ANALYSIS; POINT MUTATION; PRION DISEASE; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; CHEMISTRY; DRUG DESIGN; GENETICS; METABOLISM; MUTATION; OXIDATION REDUCTION REACTION; PRION; PROTEIN SECONDARY STRUCTURE;

BINDING SITES; DRUG DESIGN; HUMANS; METHIONINE; MOLECULAR DYNAMICS SIMULATION; MUTATION; OXIDATION-REDUCTION; PRION DISEASES; PRIONS; PROTEIN STRUCTURE, SECONDARY; SOLVENTS;

EID: 79955729783     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019093     Document Type: Article

References (57)

1. Prusiner SB, (2001) Shattuck lecture-Neurodegenerative diseases and prions. N Engl J Med 344: 1516-1526.
2. Aguzzi A, Calella AM, (2009) Prions: protein aggregation and infectious diseases. Physiol Rev 89: 1105-1152.
3. Cohen FE, Pan KM, Huang Z, Baldwin M, Fletterick RJ, et al. (1994) Structural clues to prion replication. Science 264: 530-531.
4. Gasset M, Baldwin MA, Lloyd DH, Gabriel JM, Holtzman DM, et al. (1992) Predicted alpha-helical regions of the prion protein when synthesized as peptides form amyloid. Proc Natl Acad Sci USA 189: 10940-10944.
5. Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, et al. (1993) Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl. Acad Sci USA 90: 10962-10966.
6. Eisenberg D, Nelson R, Sawaya MR, Balbirnie M, Sambashivan S, et al. (2006) The structural biology of protein aggregation diseases: Fundamental questions and some answers. Acc Chem Res 39: 568-575.
7. Makarava N, Kovacs GG, Bocharova O, Savtchenko R, Alexeeva I, et al. (2010) Recombinant prion protein induces a new transmissible prion disease in wild-type animals. Acta Neuropathol 119: 177-187.
8. Teng PK, Eisenberg D, (2009) Short protein segments can drive a non-fibrillizing protein into the amyloid state. Protein Eng Des Sel 22: 531-56.
9. Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, et al. (2007) Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature 447: 453-457.
10. Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R, et al. (1996) NMR structure of the mouse prion protein domain PrP(121-231). Nature 382: 180-182.
11. Zahn R, Liu A, Lührs T, Riek R, von Schroetter C, et al. (2000) NMR solution structure of the human prion protein. Proc Natl Acad Sci USA 97: 145-150.
12. Calzolai L, Lysek DA, Güntert P, von Schroetter C, Riek R, et al. (2000) NMR structures of three single-residue variants of the human prion protein. Proc Natl Acad Sci USA 97: 8340-8345.
13. Gossert AD, Bonjour S, Lysek DA, Fiorito F, Wüthrich K, (2005) Prion protein NMR structures of elk and of mouse/elk hybrids Proc Natl Acad Sci USA 102: 646-650.
14. Chakroun N, Prigent S, Dreiss CA, Noinville S, Chapuis C, et al. (2010) The oligomerization properties of prion protein are restricted to the H2H3 domain. FASEB J 24: 3222-3231.
15. Adrover M, Pauwels K, Prigent S, de Chiara C, Xu Z, et al. (2010) Prion fibrillization is mediated by a native structural element that comprises helices H2 and H3. J Biol Chem 285: 21004-21012.
16. Cobb NJ, Sonnichsen FD, McHaourab H, Surewicz WK, (2007) Molecular architecture of human prion protein amyloid: a parallel, in-register beta-structure. Proc Natl Acad Sci USA 104: 18946-18951.
17. Tycko R, Savtchenko R, Ostapchenko VG, Makarava N, Baskakov IV, (2010) The α-Helical C-Terminal Domain of Full-Length Recombinant PrP Converts to an In-Register Parallel β-Sheet Structure in PrP Fibrils: Evidence from Solid State Nuclear Magnetic Resonance. Biochemistry 49: 9488-9497.
18. Liemann S, Glockshuber R, (1999) Influence of amino acid substitutions related to inherited human prion diseases on the thermodynamic stability of the cellular prion protein. Biochemistry 38: 3258-3267.
19. van der Kamp MW, Daggett V, (2010) Pathogenic Mutations in the Hydrophobic Core of the Human Prion Protein Can Promote Structural Instability and Misfolding. J Mol Biol 404: 732-748.
20. Swietnicki W, Petersen RB, Gambetti P, Surewicz WK, (1998) Familial mutations and the thermodynamic stability of the recombinant human prion protein. J Biol Chem 273: 31048-31052.
21. Zhang YB, Swietnicki W, Zagorski MG, Surewicz WK, Sönnichsen FD, (2000) Solution structure of the E200K variant of human prion protein- Implications for the mechanism of pathogenesis in familial prion diseases. J Biol Chem 275: 33650-33654.
22. Vanik DL, Surewicz WK, (2002) Disease-associated F198S mutation increases the propensity of the recombinant prion protein for conformational conversion to scrapie-like form. J Biol Chem 277: 49065-49070.
23. Apetri AC, Surewicz K, Surewicz WK, (2004) The effect of disease-associated mutations on the folding pathway of human prion protein. J Biol Chem 279: 18008-18014.
24. Hegde RS, Mastrianni JA, Scott MR, DeFea KA, Tremblay P, et al. (1998) A transmembrane form of the prion protein in neurodegenerative disease. Science 279: 827-834.
25. Mishra RS, Bose S, Gu Y, Li R, Singh N, (2003) Aggresome formation by mutant prion proteins: the unfolding role of proteasomes in familial prion disorders. J Alzheimers Dis 5: 15-23.
26. Ashok A, Hegde RS, (2009) Selective processing and metabolism of disease-causing mutant prion proteins. PLoS Pathog 5: e1000479.
27. Piccardo P, Liepnieks JJ, William A, Dlouhy SR, Farlow MR, et al. (2001) Prion proteins with different conformations accumulate in Gerstmann-Sträussler-Scheinker disease caused by A117V and F198S mutations. Am J Pathol 158: 2201-2207.
28. Colacino S, Tiana G, Broglia RA, Colombo G, (2006) The determinants of stability in the human prion protein: insights into folding and misfolding from the analysis of the change in the stabilization energy distribution in different conditions. Proteins 62: 698-707.
29. Rossetti G, Giachin G, Legname G, Carloni P, (2010) Structural facets of disease-linked human prion protein mutants: A molecular dynamic study. Proteins 78: 3270-3280.
30. Chen W, van der Kamp MW, Daggett V, (2010) Diverse effects on the native β-sheet of the human Prion Protein due to disease-associated mutations. Biochemistry 49: 9874-9881.
31. Hirschberger T, Stork M, Schropp B, Winklhofer KF, Tatzelt J, et al. (2006) Structural instability of the prion protein upon M205S/R mutations revealed by molecular dynamics simulations. Biophys J 90: 3908-3918.
32. Colombo G, Meli M, Morra G, Gabizon R, Gasset M, (2009) Methionine sulfoxides on prion protein Helix-3 switch on the alpha-fold destabilization required for conversion. PLoS One 4: e4296.
33. Lisa S, Meli M, Cabello G, Gabizon R, Colombo G, et al. (2010) The structural intolerance of the PrP alpha-fold for polar substitution of the helix-3 methionines. Cell Mol Life Sci 67: 2825-2838.
34. Canello T, Frid K, Gabizon R, Lisa S, Friedler A, et al. (2010) Oxidation of Helix-3 methionines precedes the formation of PK resistant PrP. PLoS Pathog 6: e1000977.
35. Canello T, Engelstein R, Moshel O, Xanthopoulos K, Juanes ME, et al. (2008) Methionine sulfoxides on PrPSc: a prion-specific covalent signature. Biochemistry 47: 8866-8873.
36. Wolschner C, Giese A, Kretzschmar HA, Huber R, Moroder L, et al. (2009) Design of anti- and pro-aggregation variants to assess the effects of methionine oxidation in human prion protein. Proc Natl Acad Sci U S A 106: 7756-7761.
37. Scarabelli G, Morra G, Colombo G, (2010) Predicting interaction sites from the energetics of isolated proteins: a new approach to epitope mapping. Biophys J 98: 1966-1975.
38. Antonyuk SV, Trevitt CR, Strange RW, Jackson GS, Sangar D, et al. (2009) Crystal structure of human prion protein bound to a therapeutic antibody Proc Natl Acad Sci U S A 106: 2554-2558.
39. Korth C, Stierli B, Streit P, Moser M, Schaller O, et al. (1997) Prion (PrPSc)-specific epitope defined by a monoclonal antibody. Nature 390: 74-77.
40. Peretz D, Williamson RA, Kaneko K, Vergara J, Leclerc E, et al. (2001) Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412: 739-743.
41. Polymenidou M, Moos R, Scott M, Sigurdson C, Shi YZ, et al. (2008) The POM monoclonals: a comprehensive set of antibodies to non-overlapping prion protein epitopes. PLoS One 3: e3872.
42. Kuwata K, Nishida N, Matsumoto T, Kamatari YO, Hosokawa-Muto J, et al. (2007) Hot spots in prion protein for pathogenic conversion. Proc Natl Acad Sci U S A 104: 11921-11926.
43. Yamamoto N, Kuwata K, (2009) Regulating the conformation of prion protein through ligand binding. J Phys Chem B 113: 12853-12856.
44. Kaneko K, Zulianello L, Scott M, Cooper CM, Wallace AC, et al. (1997) Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc Natl Acad Sci USA 94: 10069-10074.
45. Horiuchi M, Baron GS, Xiong LW, Caughey B, (2001) Inhibition of interactions and interconversions of prion protein isoforms by peptide fragments from the C-terminal folded domain. J Biol Chem 276: 15489-15497.
46. Eghiaian F, Grosclaude J, Lesceu S, Debey P, Doublet B, et al. (2004) Insight into the PrPC->PrPSc conversion from the structures of antibody-bound ovine prion scrapie-susceptibility variants. Proc Natl Acad Sci USA 101: 10254-10259.
47. Goldmann W, Houston F, Stewart P, Perucchini M, Foster J, et al. (2006) Ovine prion protein variant A136R154L168Q171 increases resistance to experimental challenge with bovine spongiform encephalopathy agent. J Gen Virol 87: 3741-3745.
48. Nicoll AJ, Trevitt CR, Tattum MH, Risse E, Quarterman E, et al. (2010) Pharmacological chaperone for the structured domain of human prion protein. Proc Natl Acad Sci U S A 107: 17610-17615.
49. Christen B, Hornemann S, Damberger FF, Prion protein Wüthrich K, (2009) NMR structure from tammar wallaby (Macropus eugenii) shows that the beta2-alpha2 loop is modulated by long-range sequence effects. J Mol Biol 389: 833-845.
50. Sigurdson CJ, Nilsson KP, Hornemann S, Heikenwalder M, Manco G, et al. (2009) De novo generation of a transmissible spongiform encephalopathy by mouse transgenesis. Proc Natl Acad Sci U S A 106: 304-309.
51. Hilser V, (2010) Biochemistry. An ensemble view of allostery. Science 237: 653-634.
52. Smock RG, Gierasch LM, (2009) Sending signals dynamically. Science 324: 198-203.
53. Boehr DD, Nussinov R, Wright PE, (2009) The role of dynamic conformational ensembles in biomolecular recognition. Nat Chem Biol 5: 789-96.
54. Stadtman ER, (2006) Protein oxidation and aging. Free Radic Res 40: 1250-1258.
55. Brown DR, (2005) Neurodegeneration and oxidative stress: prion disease results from loss of antioxidant defence. Folia Neuropathol 43: 229-243.
56. Eghiaian F, Daubenfeld T, Quenet Y, van Audenhaege M, Bouin AP, et al. (2007) Diversity in prion protein oligomerization pathways results from domain expansion as revealed by hydrogen/deuterium exchange and disulfide linkage. Proc Natl Acad Sci U S A 104: 7414-7419.
57. Vriend G, (1990) What if: a molecular modeling and drug design program. J Mol Graph 8: 52-56.